Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521793 | 0.83 | GAA (0.57) | GAARAB9ANPC1SMN1; SMN2AURKA | |
| SCHEMBL578661 | 0.83 | GAA (0.57) | GAARAB9ANPC1SMN1; SMN2AURKA | |
| SCHEMBL10002050 | 0.77 | CSNK1A1 (0.49) | GAALMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL578958 | 0.75 | GAA (0.54) | GAARAB9ANPC1SMN1; SMN2AURKA | |
| SCHEMBL10745912 | 0.72 | KDM6B (0.49) | GAAMAPTKMT2AMEN1 | |
| SCHEMBL15349417 | 0.71 | EGLN1 (0.47) | GAAMAPTL3MBTL1 | |
| SCHEMBL10787908 | 0.71 | NPC1 (0.47) | GAARAB9ANPC1MAPTL3MBTL1 | |
| SCHEMBL12439046 | 0.71 | AURKA (0.62) | RAB9ANPC1SMN1; SMN2AURKAMAPT | |
| SCHEMBL2127792 | 0.70 | SMN1; SMN2 (0.74) | GAALMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15349502 | 0.70 | EGLN1 (0.48) | GAAMAPTKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | GAA 2151/4885LMNA 1687/4885RAB9A 2859/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | GAA 2151/4885LMNA 1687/4885RAB9A 2859/4885 |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | GAA 2151/4885LMNA 1687/4885RAB9A 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.